United States Hospital Acquired Disease Testing Market Share, Size, Growth, Opportunity and Forecast 2021-2026

*As the coronavirus disease (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the purchase behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.

United States Hospital Acquired Disease Testing Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

Market Overview:

The United States hospital acquired disease testing market is currently witnessing strong growth. Hospital-acquired diseases (HADs) are infections acquired during hospital visits or stays. They are commonly known as nosocomial infections and are caused by bacterial, fungal and viral pathogens. Some of the commonly used HAD testing techniques include the complete blood count (CBC) test, erythrocyte sedimentation rate (ESR) test, urinalysis and analysis of the infected area, blood, urine and other body fluids. These techniques assist in the diagnosis of conditions such as urinary tract infections (UTI), surgical site infections (SSI) and hospital-acquired pneumonia (HAP).

The increasing prevalence of hospital acquired infections (HAIs) and diseases in the United States is one of the key factors driving the growth of the market. Furthermore, the increasing awareness regarding the benefits of the early detection of these diseases is providing a boost to the market growth. Healthcare providers are also emphasizing on maintaining adequate hygiene in hospitals, clinics and other healthcare centers to minimize the risks of HADs. Additionally, various technological innovations, such as the development of microarrays, polymerase chain reaction (PCR), solid phase hybridization and real-time location systems (RTLSs) for preventing and monitoring HAIs, are contributing to the market growth. Looking forward, IMARC Group expects the market to continue its strong growth during 2021-2026.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the United States hospital acquired disease testing market report, along with forecasts for growth at the region level from 2021-2026. Our report has categorized the market based on region and indication.

Breakup by Indication:

UTI (Urinary Tract Infection)
SSI (Surgical Site Infection)
Pneumonia
Bloodstream Infections
MRSA (Methicillin-Resistant Staphylococcus Aureus)
Others

Breakup by Region:

Northeast
Midwest
South
West

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players.

Key Questions Answered in This Report:

How has the United States hospital acquired disease testing market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the United States hospital acquired disease testing market?
What are the key regional markets?
What is the breakup of the market based on the indication?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the United States hospital acquired disease testing market and who are the key players?
What is the degree of competition in the industry?